Launch of a clinical study by the Promedior company
Patient recruitment to a clinical study by the Promedior company will be launched probably in July 2016. The Department of Pulmonary Medicine at the Thomayer Hospital will be the only centre in the Czech Republic participating in this study. A new antibody against pentraxin will be tested in this trial; according to the study sponsor, this antibody is the first drug ever which might not only slow down the disease progression, but also lead to a decrease in fibrotic changes.
Suitable trial candidates involve IPF patients (including those treated with nintedanib and/or pirfenidone) aged 40–80, with percent predicted FVC ranging from 90% to 50%, and percent predicted DLCO ranging between 90% and 25%. The drug will be administered by intravenous infusion, the trial will be performed for 24 weeks and will be placebo-controlled, i.e. one third of patients will be given placebo.
More detailed information is available on request:
Martina Sterclova, MD, PhD
Department of Pulmonary Medicine
Thomayer Hospital
Videnska 800
140 00 Prague
Czech Republic
e-mail: martina.sterclova@ftn.cz
2. 7. 2016
   |
  |